Stonnington Group’s Pacira BioSciences PCRX Stock Holding History

Stonnington Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$507K	Sell	12,019 -2,000	-14%	-$79.6K	0.13%	147
2022 Q4	$524K	Sell	14,019 -15,500	-53%	-$754K	0.14%	124
2022 Q3	$1.57M	Buy	29,519 +6,422	+28%	+$357K	0.44%	64
2022 Q2	$1.34M	Sell	23,097 -23,500	-50%	-$1.54M	0.36%	67
2022 Q1	$3.41M	Buy	46,597 +1,050	+2%	+$70K	0.82%	35
2021 Q4	$2.83M	Buy	45,547 +24,100	+112%	+$1.33M	0.61%	50
2021 Q3	$1.03M	Sell	21,447 -4,100	-16%	-$236K	0.23%	107
2021 Q2	$1.44M	Buy	25,547 +500	+2%	+$31.6K	0.32%	87
2021 Q1	$1.55M	Buy	+25,047	New	+$1.79M	0.38%	76

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Stonnington Group's PCRX Position: Q1 2023 in Review

Stonnington Group reduced its Pacira BioSciences (PCRX) stake by 14% in Q1 2023, selling an estimated $79.6K and leaving 12,019 shares worth $507K. The position accounts for 0.13% of the portfolio, ranked #147.

Stonnington Group first reported a position in PCRX in Q1 2021 and has held it in 9 quarters since. The position peaked at $3.41M in Q1 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

Stonnington Group held 12,019 shares of Pacira BioSciences worth $507K as of Q1 2023.
Stonnington Group sold 2,000 Pacira BioSciences shares in Q1 2023, an estimated $79.6K.
Pacira BioSciences made up 0.13% of Stonnington Group's portfolio in Q1 2023, its #147 holding.
Stonnington Group first reported a position in Pacira BioSciences in Q1 2021 and has held it in 9 quarters since.
Stonnington Group's Pacira BioSciences position peaked at $3.41M in Q1 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.